Abstract:BACKGROUND & AIMS: B cells infiltrate tumors, but little is known about how they affect tumor growth and progression. microRNA15A (MIR15A or miRNA15A) and microRNA16-1 (MIR16-1 or miRNA16-1) regulate cell proliferation, apoptosis, and drug resistance. We investigated their involvement in B-cell-mediated immune suppression by colorectal tumors. METHODS: Mice with disruptions of the gene cluster that encodes MIR15A and MIR16-1 (knockout mice), and control (C57BL/B6) mice were given azoxymethane with dextran sodium sulfate (AD) to induce formation of colorectal tumors. Mice were given anti-CD20 to delete B cells, or injections of agomir to increase MIR15A and MIR16-1. Proliferation of CD8(+)T cells was measured by carboxyfluorescein-succinimidyl-ester analysis. Colon tissues were collected from mice and analyzed by flow cytometry, microRNA (miRNA) sequencing, and for cytokine production. Intestinal epithelial cells (IECs) were isolated and transfected with miRNA mimics, to identify their targets. We analyzed miRNA expression patterns and quantified B cells in colorectal cancer tissue microarrays derived from 90 patients who underwent surgical resection, from July 2006 through April 2008, in Shanghai, China; expression data were compared with clinical outcomes. RESULTS: Tumors that developed in knockout mice following administration of AD were larger and contained greater numbers of B cells than tumors that grew in control mice. Most of the B cells in the tumors were positive for immunoglobulin A (IgA(+)). IgA(+) B cells expressed high levels of immune regulatory molecules (programmed death ligand 1, interleukin 10, and transforming growth factor beta), and repressed the proliferation and activation of CD8(+) T cells. Levels of MIR15A and MIR16-1 were reduced in colon tumors from mice, compared with nontumor colon tissue. Incubation of IECs with IL17A reduced expression of MIR15A and MIR16-1. Transgenic expression of MIR15A and MIR16-1 in IECs decreased activation of NF-kappa B and STAT1 by reducing expression of I-kappaB kinases; this resulted in reduced production of chemokine (C-X-C motif) ligands 9 and 10 and decreased chemotaxis of IgA(+) B cells. Tumors in mice injected with AD and agomir grew more slowly than tumors in mice not given in agomir and contained fewer IgA(+) B cells. We found a negative correlation between levels of MIR15A and MIR16-1 and numbers of IgA(+)B cells in human colorectal tumor tissues; high levels of MIR15A and MIR16-1 and low numbers of IgA(+)B cells were associated with longer survival times of patients. CONCLUSIONS: We found increased levels of MIR15A and MIR16-1 to reduce numbers of IgA(+)B cells in colorectal tumor tissues and correlate with increased survival time of patients. In mice that lack MIR15A and MIR16-1, colon tumors grow more rapidly and contain increased numbers of IgA(+)B cells. MIR15A and MIR16-1 appear to activate signaling pathways required for B-cell-mediated immune suppression.

Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Identification of Necroptosis-Related Long Noncoding RNAs for Immunotherapy Selection and Prognosis Prediction in Patients with Colorectal Cancer

Pathological Significance of Abnormal Recepteur D’origine Nantais and Programmed Death Ligand 1 Expression in Colorectal Cancer

Prognostic Value of Immune Scores in the Microenvironment of Colorectal Cancer

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Low Mutation Burden and Differential Tumor-Infiltrating Immune Cells Correlate with Lymph Node Metastasis in Colorectal Cancer

Neuromedin U contributes to radiation resistance in colorectal cancer via YAP/TAZ signaling activation

Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer

Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation

MicroRNAs 15A and 16–1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B Cells to Colorectal Tumors

Development of a Metastasis-Related Immune Prognostic Model of Metastatic Colorectal Cancer and Its Usefulness to Immunotherapy

Abstract 454: microRNAs role in innate immunosenescence during anti-PD1 immunotherapy

Immune Prognostic Model for Predicting the Recurrence and the Response to Chemo/Immunotherapy in Metastatic Colorectal Cancer

MicroRNAs: Novel Immunotherapeutic Targets in Colorectal Carcinoma.

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study

Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer

Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer

LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions

Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer

Data from Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer